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The Impact of Alzheimer's Disease - The Silent Killer
Abstract

With a rise in life expectancy and the lack of a specific known cause, Alzheimer's disease is preying on our
senior citizens worldwide at an alarming rate. This paper will explain what Alzheimer’s disease is medically,
treatments we have at our disposal, preventative measures, and education on the rising economic burden.
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Alzheimer’s disease is a progressive medical disorder that affects nerve cells in areas of
the brain responsible for memory, cognition, language, and motor activity. Neurons, or nerve
cells, in the brain transmit signals to and from multiple areas of the brain and central nervous
system, with a chemical called acetylcholine. Binding of acetylcholine from one neuron to
another is the very basis of brain activity, and the neurons responsible for producing
acetylcholine are affected by Alzheimer’s disease. As Alzheimer’s disease progresses
acetylcholine production is reduced and neurons slowly lose function and begin to die after
which neurons and neurotransmitters can no longer be reproduced or repaired (Alzheimer’s
Association, 2016; National Institute on Aging, 2016; Webster’s Medical Dictionary, 2016).
The area in the brain responsible for memory retention is the hippocampus, and it is
commonly the first area to be affected by Alzheimer’s disease. In a healthy brain the
hippocampus becomes active during memory formation and retrieval. In a brain affected by
Alzheimer’s disease, forming new and retrieving old memories becomes increasingly more
difficult due to the loss of acetylcholine-producing neurons in the hippocampus. As hippocampal
neurons continue to decay, communication between nerve cells is permanently lost. Most
commonly memory loss is one of the first observable symptoms of Alzheimer’s disease
(Alzheimer’s Association, 2016; National Institute on Aging, 2016; Webster’s Medical
Dictionary, 2016).
Multiple areas in the brain are responsible for cognition, including the frontal cortex,
occipital lobes, and hippocampus. Cognitive abilities require communication and transfer of
information from all of these brain regions. Nerve cell damage in any of these areas hinders
thinking abilities and problem-solving skills (Alzheimer’s Association, 2016; National Institute
on Aging, 2016; Webster’s Medical Dictionary, 2016).
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Motor activity is generated in the motor cortex, which is located in the frontal lobe. As
neurons decay and die in the motor cortex, movement becomes increasingly difficult and
proceeds to a total loss of mobility (National Institute on Aging, 2016).
The Alzheimer’s foundation of America (AFA) identifies three stages of Alzheimer’s
disease as mild, moderate, and severe. These stages reflect the movement of the disease from the
central areas of the brain outward. As the disease progresses the symptoms become more severe
(Alzheimer’s Foundation of America, 2016).
In the mild stage of Alzheimer’s disease, the hippocampus appears to be the area
affected the most. Patients experience short-term memory loss, most often have trouble
remembering what they were doing, saying, or where they were going. Patients often find
themselves more confused and find themselves struggling to remember the steps needed to
complete a previously normal task. Complaints of memory loss are often the first indication that
a person is suffering from Alzheimer’s disease. Patients begin to have increased trouble
speaking and understanding what other people are saying, this could perhaps be because of the
inability to remember words and word meanings. Patients begin to need outside assistance.
Family and friends will also begin to notice unexpected behaviors and personality changes
(Alzheimer’s Association, 2016).
In the moderate stage of Alzheimer’s disease, patients begin to lose long-term memory
as well as permanent loss of short term memories. The ability to learn new tasks is extremely
limited. In this stage the areas responsible for memories of specific information such as facial
recognition rapidly begins to decline, with intermittent bouts of lucidity. The spread of the
disease from the central brain regions outward is now noticeable as patients begin to lose the
ability to differentiate between and recognize family members. Processing sensory information
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or normal reasoning is also inhibited by the degeneration of neurons. Patients now need complete
supervision and assistance with tasks such as washing and feeding themselves, indicating that the
disease has now spread to the motor areas. In some cases, patients in this stage experience
hallucinations, delusions, paranoia, and impulsivity indicating that sensory areas of the brain are
degenerating as well (Alzheimer’s Association, 2016; Alzheimer’s Foundation of America,
2016).
The severe stage of Alzheimer’s disease proceeds towards death. The extensive
amount of degeneration of the brain’s neurons (see Fig. 1) leads to profound loss of abilities.
Patients can no longer communicate and are completely dependent on outside care. The loss of
motor neurons is so profound that the patient can no longer swallow or breathe on their own. The
body completely shuts down as the brain shrinks and dies (National Institute on Aging, 2016).

Figure 1

Shown here are two representation images of a healthy brain and a brain afflicted with severe
Alzheimer’s disease. The National Institute on Aging (2016) shows the extreme atrophy that
Happens in the hippocampus and cerebral cortex. With Alzheimer’s disease the brain shrinks
and eventually dies.

What people do not know about Alzheimer’s disease.
Considerable survey research has been conducted asking people what they know about
Alzheimer’s disease, including what people know about the disease and its symptoms. The
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survey asked whether people think that Alzheimer’s disease is curable, treatable, reversible or
fatal, and also inquired about whether there was an accurate test to determine whether someone
has the disease (Harvard School of Public Health, 2011; National Institute on Aging, 2016;
Alzheimer’s Foundation of America, 2016).
According to one study, the population surveyed did not seem to understand that
Alzheimer’s disease is a serious disease. The Harvard School of Public Health (2011) completed
a phone study asking people from five countries, one of which was the United States, to rank
their fear of diseases, from the the most to least fearful. The list included cancer, heart disease,
stroke, Alzheimer’s disease, diabetes, depression, and influenza. The results showed that in four
of the five countries, cancer was the most feared disease by all participants. In those four
countries, Alzheimer’s disease was rated the second most fearful disease by only 25% of the
participants. Ironically, all of the diseases are curable or manageable with treatment, except
Alzheimer’s disease, which suggests that most people have insufficient information about
Alzheimer’s disease.
The Harvard School of Public Health (2011) survey included 2678 respondents, most
reported low fear of Alzheimer’s disease. In addition, fewer than half recognized that
Alzheimer’s is a fatal disease, when in fact Alzheimer’s if the seventh leading cause of death in
high income countries. Alzheimer’s disease is the only cause of death among the top ten causes
of death in the United States that cannot be clinically prevented or effectively treated. Multiple
studies show that Alzheimer’s disease might eventually become one of the most prominent
causes of death because of improper diagnosis, improper data collection, and lack of proper
health insurance (National Institute on Aging, 2016).
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In addition to lack of fear of Alzheimer’s disease and knowledge of fatality of
Alzheimer’s disease, respondents of the HPSH (2011) study reported that they believe there is
now an effective medical or pharmaceutical treatment to slow the progression of Alzheimer’s
disease. The study also shows that most people believe there is medication that will make the
symptom of Alzheimer’s disease less severe.
However, according to the Alzheimer’s Association (2016) there are two FDA approved
medications-- cholinesterase inhibitors and memantine. The pharmaceutical treatments approved
by the Food and Drug Administration in the United States only temporarily help symptoms, they
are not effective treatments or cures (see Fig. 2). For example, 47% of respondent from the
United States think there is an effective treatment to alleviate symptoms.
The current FDA approved treatments include cholinesterase inhibitors which
temporarily help to prevent the breakdown of acetylcholine, delaying symptoms for as much as
six to twelve months. This medication is generally prescribed in the mild to early moderate stage
of AD. Aricept, Razadyne, and Exelon are the most common cholinesterase inhibitors prescribed
(Alzheimer’s Association, 2016).
Memantine regulates the activity of glutamate, a neurotransmitter involved in learning
and memory retention. Memantine delays the progression of symptoms for some people
temporarily. Many experts consider its benefits similar to those of cholinesterase inhibitors.
Nemenda is most commonly prescribed and is only approved for moderate to severe Alzheimer’s
disease (Alzheimer’s Association, 2016).
The Harvard School of Public Health (2011) also reported that nearly half of respondents
believed that there was an effective test to determine if a patient is suffering from Alzheimer’s
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disease, for example, in the United States, 59% of respondents reported that they thought there is
a reliable and accurate test for Alzheimer’s disease (see Fig. 2).

Figure 2

The truth is that current medical test are ineffective in diagnosing Alzheimer’s disease.
Neurons affected by Alzheimer’s disease start to deteriorate as much as ten to twenty years
before symptoms begin to affect the patient. Typically, patients are diagnosed in the mild stage
of Alzheimer’s disease, when memory problems begin. Damage to the brain areas affected by
Alzheimer’s disease is already severe at the mild stage of the disease. Degeneration in the
hippocampus, the frontal cortex, and occipital lobes is irreversible by this time. With no way to
halt or reverse the decline of memory and cognitive abilities, discovering the death of
neurotransmitters and nerve cells well before symptoms occur is necessary to alleviate symptoms
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and develop better treatments. Having better diagnostic tools will be the only way to enable that
to happen (Landau, 2011).
Current Diagnostic Methods
The Mayo Clinic (2016) has published a set of diagnostic tests because at this time
there is no single medical test to determine if a person is suffering from Alzheimer’s disease.
Diagnosis is difficult and requires extensive and careful medical evaluation. Because neurons
affected by Alzheimer’s disease begin to decay the amount of healthy neurotransmitters as much
as ten to twenty years before symptoms begin to affect the patient, damage is already pronounced
at the mild stage of the disease. Typically, patients are diagnosis in the Mild stage of Alzheimer’s
disease. Brain areas that have already deteriorated when diagnosis has been made are the
hippocampus, the frontal cortex, and occipital lobes and at this stage of degeneration the damage
is irreversible (Landau, 2011).
The Mayo Clinic tests (2016) include a thorough medical history, physical exams, and
neurological exams. The physical tests include testing reflexes, coordination, sight and hearing,
and muscle tone and strength. These tests determine if testing for Alzheimer’s should proceed.
Lab tests determine that conditions such as thyroid disorders, vitamin deficiencies, and diabetes
are not causes of memory loss and confusion. An extensive mental status assessment is
performed to assess cognitive function.
The Mayo Clinic suggests the use of brain imaging such as CT scans to rule out tumors,
strokes, and head injuries as causes for patient’s symptoms. MRI scans are used to assess if brain
atrophy implicates Alzheimer’s disease as the cause of symptoms. Recently improved PET scans
use glucose to show brain activity and can also show brain levels of amyloid plaques and tangles,
two brain abnormalities associated with Alzheimer’s disease. Unfortunately, the new PET scans
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are not yet available to all medical doctors. Theses PET techniques are only found in research
and clinical trial settings (Mayo Clinic, 2016).
Cerebrospinal fluid can be tested for biomarkers that indicate a genetic factor for early
on-set Alzheimer’s disease (Mayo Clinic, 2016). Only a small fraction of 1% of people
worldwide have the rare genetic form of Alzheimer’s disease, these people tend to show signs of
amyloid plaques in PET scans and in cerebrospinal fluid tests. Another biomarker of interest is
tau, which is implicated in the development of neurofibrillary tangles that build up in the brains
of Alzheimer’s disease patients. Notably these tangles are found in the hippocampus or memory
center of the brain. Tau mimics the shape of healthy cells and destroys them, however genetic
testing for this biomarker is implausible at this time as there is no scan to detect the tau in a
living patient (Landau, 2010).
Currently the diagnosis of Alzheimer’s disease is difficult because no specific cause
has been discovered. With no specific cause identified, there are no reliable treatments to cure or
reverse the atrophy that develops in the brain afflicted with Alzheimer’s disease. Improved
participant numbers in research and clinical trials will lead to a far superior diagnostic system
and an opportunity to develop sophisticated tools for earlier diagnosis. In addition to advancing
diagnosis increased research will inevitably lead to scientific breakthroughs in the discovery of a
cure.
Economic Burden of Alzheimer’s Disease
Alzheimer’s disease will affect millions of people if adequate treatment is not
discovered, and right now curing Alzheimer’s is not plausible in the near future. As life
expectancy increases worldwide, the number of aging adults has exponentially risen. With the
increase of the aged population, the prevalence of Alzheimer’s disease is aggressively rising,
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along with a parallel increase in the economic burden of caring for a populace with a chronic
incurable disease. In the United States alone we are spending over $200 billion dollars each year
to treat AD patients, with Medicare shouldering the majority of the cost. Chronic disease in our
aging population could bankrupt Medicare (National Institute on Aging, 2016). The global
economic effect could be devastating. Multiple studies on the financial impact of Alzheimer’s
disease are anticipating one out of 85 people will suffer from Alzheimer’s disease worldwide by
the year 2050. Caring for AD patients in that magnitude is expected to cost billions, if not
trillions, of dollars. (Brookmeyer, Johnson, Zeigler-Graham & Arrighi, 2007; Brookmeyer, Grey
& Kawas, 1998; Rocca et al. 2011).
The annual economic cost of Alzheimer’s disease in the United States for lost wages
is between 80-100 billion dollars, costing America $236 billion dollars yearly. Alzheimer’s
disease is the third largest and costly disease after cancer and heart disease. With lack of proper
patient care, exorbitant institutional care, and financial burden on caregivers, this number will
only increase. More than 15 million caregivers provide an average of 18 billion hours of unpaid
care, and the immediate financial burdens falls heavily on single income family members.
Beyond the obvious financial burdens, care contributors lose over $15,000 in annual income as a
result of reducing or quitting work to meet the demands of caregiving. The Alzheimer’s
Association (2016) commissioned a nationwide scientific survey of more than 3,500 Americans
and reported that “[a]larmingly, the survey revealed that many care contributors had to cut back
on basic necessities such as food and medical care for themselves and their families. They are 28
percent more likely than other adults to eat less or go hungry because they cannot afford to pay
for food” (Alzheimer’s Association, 2016, p. 6).
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When stacked financially against the annual cost of caring for cancer and heart disease,
Alzheimer’s is a major contender in the economic health crisis. The agency for Healthcare
Research and Quality (AHRQ) estimates that the direct medical cost (total of all health care cost)
for cancer in the United States annually is $895 billion dollars and the estimate for heart disease
is $753 billion dollars (Agency for Healthcare Research and Quality, 2016).
Prevention
With the list of chronic diseases growing and the shortage of funding for research
being stretched, the major focus today seems to be preventing Alzheimer’s disease (Pope, Shue,
& Beck, 2003). Focusing on prevention at an early age could reduce risk factors by as much as
25-45%. Reducing the risk of factors believed to be correlated with AD, such as heart disease,
high blood pressure, diabetes, obesity, and depression may lead to a decreased risk of developing
late on-set Alzheimer’s disease, and reduce risk of developing the related diseases as well (Pope,
Shue, & Beck, 2003).
Ongoing research is needed to directly relate the correlation between those diseases
and Alzheimer’s disease. Cognitive abilities decline naturally with age, and when compounded
with Alzheimer’s disease atrophy and unstable molecules or free radical production is rapid.
Loss of connection between neurons creates a permanent loss of communication between the
areas of the brain, such as the frontal cortex, the hippocampus, the motor cortex and the sensory
cortex. Without these neurons the brain will no longer communicate with body’s muscles and
organs. Research indicates that there are no straightforward answers on how to prevent
Alzheimer’s disease. Multiple studies have shown that a multifaceted prevention plan can reduce
the risk factors in developing Alzheimer’s disease (Brookmeyer, Grey, & Kawas, 1998; Landau,
2011; Pope, Shue, & Beck, 2003).
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Facets of healthy lifestyles begin with proper eating habits, physical activity, and
mental and social activity. Diets high in fat, saturated fat, and cholesterol have been linked to
incidental dementia, but diets rich in Omega-3 fatty acids and fish will lower total fat and total
cholesterol and will assist in reducing the risk. Healthy diets also reduce risk of Type 2 diabetes,
high blood pressure, heart disease, and obesity -- all diseases correlated with developing
Alzheimer’s disease (Pope, Shue, & Beck, 2003; Bassil, & Grossberg, 2010.
Low levels of physical activity is a risk factor in Alzheimer’s disease. Several large
studies show that higher physical activity increases life expectancy by two to five years.
Increased physical activity reduces the risk of numerous chronic diseases including heart disease,
stroke, breast cancer and colon cancer. When patients develop habits that include physical
activity such as hiking or running they are less likely to suffer cognitive impairment (Pope, Shue,
& Beck, 2003).
Continued education and cognitive activity through old age can help prolong patients’
cognitive abilities and delay the presentation of Alzheimer’s disease’s effects on memory and
cognitive function (Bassil, & Grossberg, 2010). Cognitive improvements can increase quality of
life and lower risks of depression. The Cognitive decline that can happen naturally is slightly
deterred by an increase in stimulation in the areas of the hippocampus and cerebral cortex (Stern,
2006).
According to Pope, Shue and Beck (2003), “Stress management has received little
attention as a risk factor for Alzheimer’s disease […]” (p. 124) Chronic stress may be a risk
factor for cognitive decline in Alzheimer’s disease. High cortisol, over-responding
neuroendocrine and immune systems, and stress induced hormone levels can all lead to
hippocampal damage. Reducing chronic stress will help improve quality of life and reduce the
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risk factor of chronic disease such as obesity, depression, high blood pressure and hypertension
(Pope, Shue, & Beck, 2003)
There are no clinically proven prevention measures at this time. However,
including any of the above mentioned prevention methods will decrease the risk of developing
any of the correlating diseases’ and improve the quality of life in the patient. Healthy habits
adopted early will have a positive effect in all areas of the brain, that Alzheimer’s disease
attacks.
Conclusion
More research is needed to determine if the prevention methods recommended are
in fact plausible preventive measures. Until an empirical cure has been discovered or superior
diagnostic system and treatments are in place, prevention is the only tool to combat Alzheimer’s
disease and effects on the aging populace. Raising awareness of the disease can help people
change behaviors that can prevent and delay the disease. Raising awareness will also increase the
probability that the disease will get the attention it deserves to develop effective diagnoses and
treatments. Raising awareness will ultimately lead to research to find a cure for Alzheimer’s
disease—the Silent Killer.
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